JP2015078199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015078199A5 JP2015078199A5 JP2014231450A JP2014231450A JP2015078199A5 JP 2015078199 A5 JP2015078199 A5 JP 2015078199A5 JP 2014231450 A JP2014231450 A JP 2014231450A JP 2014231450 A JP2014231450 A JP 2014231450A JP 2015078199 A5 JP2015078199 A5 JP 2015078199A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- diseases
- mek
- heptane
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 8
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 3
- 230000001404 mediated Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000003463 hyperproliferative Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- -1 2-fluoro-4-iodophenylamino Chemical group 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 210000002940 B-Lymphoid Precursor Cells Anatomy 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 208000005017 Glioblastoma Diseases 0.000 claims 1
- 206010061255 Ischaemia Diseases 0.000 claims 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 206010028549 Myeloid leukaemia Diseases 0.000 claims 1
- 208000009025 Nervous System Disease Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 102000030951 Phosphotransferases Human genes 0.000 claims 1
- 108091000081 Phosphotransferases Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000005216 brain cancer Diseases 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 201000010870 diseases of metabolism Diseases 0.000 claims 1
- 239000002532 enzyme inhibitor Substances 0.000 claims 1
- 230000003352 fibrogenic Effects 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 201000010238 heart disease Diseases 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000003211 malignant Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 210000001948 pro-B lymphocyte Anatomy 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Images
Claims (11)
- 酢酸エチルおよびヘプタンの混合物から、非結晶質のN−(−)−(3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)−6−メトキシフェニル)−l−(2,3−ジヒドロキシプロピル)シクロプロパン−1−スルホンアミドを結晶化することを含む、N−(−)−(3,4−ジフルオロ−2−(2−フルオロ−4−ヨードフェニルアミノ)−6−メトキシフェニル)−l−(2,3−ジヒドロキシプロピル)シクロプロパン−1−スルホンアミドの多形体の製造方法。
- 前記酢酸エチルおよびヘプタンの混合物は、ヘプタン2〜10部に対して酢酸エチル1〜4部の比率である、請求項2に記載の多形体の製造方法。
- 前記酢酸エチルおよびヘプタンの混合物は、ヘプタン5部に対して酢酸エチル2部の比率である、請求項2に記載の多形体の製造方法。
- 請求項1に記載の多形結晶を含み、前記多形結晶は、MEK酵素を少なくとも25%阻害するのに十分な量で存在する、MEK酵素阻害剤。
- 前記MEK酵素は、MEKキナーゼである、請求項5記載のMEK酵素阻害剤。
- 効果的な量の、請求項1に記載の多形結晶、および少なくとも1つの賦形剤または担体を含む、薬剤組成物。
- MEK媒介性疾患を治療するための、請求項7記載の薬剤組成物。
- 前記MEK媒介性疾患は、炎症性疾病、感染、自己免疫疾患、脳卒中、虚血、心疾患、神経系疾患、繊維形成性疾患、増殖性疾患、過剰増殖性疾患、腫瘍、白血病、新生物、癌、癌腫、代謝性疾患、および悪性疾患から成る群から選択される、請求項8記載の薬剤組成物。
- 前記MEK媒介性疾患は、過剰増殖性疾病である、請求項8記載の薬剤組成物。
- 前記癌は、脳腫瘍、乳癌、非小細胞肺癌を含む肺癌、卵巣癌、膵臓癌、前立腺癌、腎臓癌、結腸直腸癌、白血病、骨髄性白血病、膠芽細胞腫、濾胞性リンパ腫、前駆B細胞急性白血病、慢性Bリンパ球性白血病、胃癌、中皮腫、小細胞肺癌、または肝臓癌である、請求項9記載の薬剤組成物。
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/830,733 US8101799B2 (en) | 2005-07-21 | 2007-07-30 | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
US11/830,733 | 2007-07-30 | ||
US3446408P | 2008-03-06 | 2008-03-06 | |
US3446608P | 2008-03-06 | 2008-03-06 | |
US61/034,466 | 2008-03-06 | ||
US61/034,464 | 2008-03-06 | ||
US4488608P | 2008-04-14 | 2008-04-14 | |
US61/044,886 | 2008-04-14 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010520118A Division JP2010535232A (ja) | 2007-07-30 | 2008-07-28 | Mekの阻害剤としての多形体を含む、n−(アリールアミノ)スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017018477A Division JP2017125021A (ja) | 2007-07-30 | 2017-02-03 | Mekの阻害剤としての多形体を含む、n−(アリールアミノ)スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015078199A JP2015078199A (ja) | 2015-04-23 |
JP2015078199A5 true JP2015078199A5 (ja) | 2016-05-26 |
JP6309880B2 JP6309880B2 (ja) | 2018-04-11 |
Family
ID=40304796
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010520118A Pending JP2010535232A (ja) | 2007-07-30 | 2008-07-28 | Mekの阻害剤としての多形体を含む、n−(アリールアミノ)スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
JP2014231450A Expired - Fee Related JP6309880B2 (ja) | 2007-07-30 | 2014-11-14 | Mekの阻害剤としての多形体を含む、n−(アリールアミノ)スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
JP2017018477A Pending JP2017125021A (ja) | 2007-07-30 | 2017-02-03 | Mekの阻害剤としての多形体を含む、n−(アリールアミノ)スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010520118A Pending JP2010535232A (ja) | 2007-07-30 | 2008-07-28 | Mekの阻害剤としての多形体を含む、n−(アリールアミノ)スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017018477A Pending JP2017125021A (ja) | 2007-07-30 | 2017-02-03 | Mekの阻害剤としての多形体を含む、n−(アリールアミノ)スルホンアミドの誘導体、および組成物、使用方法、ならびにその調製方法 |
Country Status (23)
Country | Link |
---|---|
EP (1) | EP2184984A4 (ja) |
JP (3) | JP2010535232A (ja) |
KR (3) | KR20150091434A (ja) |
CN (2) | CN103479604B (ja) |
AP (1) | AP2817A (ja) |
AU (2) | AU2008282338B2 (ja) |
BR (1) | BRPI0815659A2 (ja) |
CA (1) | CA2693390C (ja) |
CO (1) | CO6470808A2 (ja) |
CR (1) | CR11244A (ja) |
DO (1) | DOP2010000045A (ja) |
EA (2) | EA020624B1 (ja) |
EC (1) | ECSP109910A (ja) |
HK (1) | HK1147396A1 (ja) |
HN (1) | HN2010000203A (ja) |
IL (1) | IL203296A (ja) |
MA (1) | MA31881B1 (ja) |
MX (1) | MX2010001244A (ja) |
NZ (1) | NZ582929A (ja) |
PH (1) | PH12015501914A1 (ja) |
SV (1) | SV2010003469A (ja) |
TN (1) | TN2010000049A1 (ja) |
WO (1) | WO2009018233A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
EP2291350A4 (en) * | 2008-04-14 | 2012-09-19 | Ardea Biosciences Inc | COMPOSITIONS AND METHODS FOR THEIR MANUFACTURE AND USE |
WO2010028968A2 (en) * | 2008-09-09 | 2010-03-18 | F. Hoffmann-La Roche Ag | Polymorphs of acyl sulfonamides |
WO2010037041A2 (en) | 2008-09-26 | 2010-04-01 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
UY32486A (es) * | 2009-03-11 | 2010-10-29 | Ardea Biosciences Inc | Tratamiento del cáncer de páncreas |
US8673876B2 (en) * | 2009-03-11 | 2014-03-18 | Ardea Biosciences Inc. | Pharmaceutical combinations for treatment of specific cancers |
CN102666512B (zh) | 2009-10-13 | 2014-11-26 | 奥斯特姆医疗公司 | 对疾病治疗有用的mek抑制剂 |
WO2011047788A1 (en) * | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
CN102649773A (zh) * | 2011-02-23 | 2012-08-29 | 苏州波锐生物医药科技有限公司 | 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途 |
AU2012249322B2 (en) * | 2011-04-28 | 2018-01-04 | Sloan-Kettering Institute For Cancer Research | HSP90 combination therapy |
PE20140580A1 (es) * | 2011-05-27 | 2014-06-01 | Bayer Ip Gmbh | Sintesis quiral de n-{3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]-6-metoxifenil}-1-[2,3-dihidroxi-propil]ciclopropanosulfonamidas |
EP2788378A4 (en) * | 2011-12-09 | 2015-09-09 | Oncomed Pharm Inc | ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
BR112014029338A2 (pt) * | 2012-05-31 | 2017-06-27 | Bayer Pharma AG | biomarcadores para determinação da resposta eficaz dos tratamentos de pacientes com carcinoma hepatocelular (hcc) |
CA3218491A1 (en) * | 2012-06-04 | 2013-12-12 | Pharmacyclics Llc | Crystalline forms of a bruton's tyrosine kinase inhibitor |
LT3702351T (lt) * | 2012-10-19 | 2024-01-10 | Array Biopharma, Inc. | Kompozicijos, apimančios mek inhibitorių |
WO2014071183A1 (en) | 2012-11-02 | 2014-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
AU2014212081A1 (en) | 2013-02-04 | 2015-08-13 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
EP2848246A1 (en) | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
EP3185900A4 (en) * | 2014-08-25 | 2018-05-02 | Aimmune Therapeutics, Inc. | Egg protein formulations and methods of manufacture thereof |
BR122023020985A2 (pt) | 2015-03-03 | 2023-12-26 | Pharmacyclics Llc | Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton |
BR112019026483A2 (pt) * | 2017-06-16 | 2020-07-14 | Beta Pharma, Inc. | formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
JP2575590B2 (ja) * | 1992-07-31 | 1997-01-29 | 塩野義製薬株式会社 | トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法 |
ATE172717T1 (de) * | 1992-08-25 | 1998-11-15 | Searle & Co | Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen |
US7115632B1 (en) * | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
EP1144394B1 (en) * | 1999-01-13 | 2005-08-24 | Warner-Lambert Company LLC | 1-heterocycle substituted diarylamines |
GB0003224D0 (en) * | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
CA2461227C (en) * | 2001-09-24 | 2012-05-15 | Jessie L.-S Au | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy |
CA2492175A1 (en) * | 2002-07-17 | 2004-01-22 | Titan Pharmaceuticals, Inc. | Combination of chemotherapeutic drugs for increasing antitumor activity |
RU2005105693A (ru) * | 2002-07-30 | 2005-07-10 | Центарис ГмбХ (DE) | Применение алкилфосфохолинов и лекарственное средство для лечения опухолевых заболеваний |
AU2006235487B2 (en) * | 2005-04-12 | 2011-12-22 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
CN101198582A (zh) * | 2005-04-22 | 2008-06-11 | 橘生药品工业株式会社 | 4’-{2-[(1s,2r)-2-羟基-2-(4-羟基苯基)-1-甲基乙氨基]乙氧基}-3-异丙基-3’,5’-二甲基联苯羧酸盐酸盐的结晶多形 |
CA2618218C (en) * | 2005-07-21 | 2015-06-30 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
JP2007099763A (ja) * | 2005-09-08 | 2007-04-19 | Toyama Chem Co Ltd | ピペラシリンナトリウム・1水和物の新規な結晶及びその製造方法 |
TW200800150A (en) * | 2005-12-21 | 2008-01-01 | Organon Nv | Compounds with medicinal effects due to interaction with the glucocorticoid receptor |
-
2008
- 2008-07-28 MX MX2010001244A patent/MX2010001244A/es active IP Right Grant
- 2008-07-28 KR KR1020157020493A patent/KR20150091434A/ko not_active Application Discontinuation
- 2008-07-28 WO PCT/US2008/071392 patent/WO2009018233A1/en active Application Filing
- 2008-07-28 KR KR1020147017261A patent/KR20140098185A/ko not_active Application Discontinuation
- 2008-07-28 CN CN201310317815.8A patent/CN103479604B/zh not_active Expired - Fee Related
- 2008-07-28 EA EA201000268A patent/EA020624B1/ru not_active IP Right Cessation
- 2008-07-28 EA EA201400552A patent/EA032294B1/ru not_active IP Right Cessation
- 2008-07-28 AU AU2008282338A patent/AU2008282338B2/en not_active Ceased
- 2008-07-28 CA CA2693390A patent/CA2693390C/en not_active Expired - Fee Related
- 2008-07-28 CN CN2008801088296A patent/CN101808516B/zh not_active Expired - Fee Related
- 2008-07-28 BR BRPI0815659-0A2A patent/BRPI0815659A2/pt not_active Application Discontinuation
- 2008-07-28 KR KR1020107004742A patent/KR20100092424A/ko active Search and Examination
- 2008-07-28 EP EP08796733.7A patent/EP2184984A4/en not_active Ceased
- 2008-07-28 AP AP2010005134A patent/AP2817A/xx active
- 2008-07-28 JP JP2010520118A patent/JP2010535232A/ja active Pending
- 2008-07-28 NZ NZ582929A patent/NZ582929A/en not_active IP Right Cessation
-
2010
- 2010-01-13 IL IL203296A patent/IL203296A/en not_active IP Right Cessation
- 2010-01-29 DO DO2010000045A patent/DOP2010000045A/es unknown
- 2010-01-29 EC EC2010009910A patent/ECSP109910A/es unknown
- 2010-01-29 TN TNP2010000049A patent/TN2010000049A1/fr unknown
- 2010-01-29 HN HN2010000203A patent/HN2010000203A/es unknown
- 2010-01-29 CO CO10009526A patent/CO6470808A2/es not_active Application Discontinuation
- 2010-01-29 CR CR11244A patent/CR11244A/es not_active Application Discontinuation
- 2010-01-29 SV SV2010003469A patent/SV2010003469A/es unknown
- 2010-02-19 MA MA32636A patent/MA31881B1/fr unknown
-
2011
- 2011-02-18 HK HK11101625.8A patent/HK1147396A1/xx not_active IP Right Cessation
-
2014
- 2014-11-14 JP JP2014231450A patent/JP6309880B2/ja not_active Expired - Fee Related
-
2015
- 2015-01-28 AU AU2015200390A patent/AU2015200390B2/en not_active Ceased
- 2015-08-28 PH PH12015501914A patent/PH12015501914A1/en unknown
-
2017
- 2017-02-03 JP JP2017018477A patent/JP2017125021A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015078199A5 (ja) | ||
JP2018520205A5 (ja) | ||
JP2012153722A5 (ja) | ||
HRP20180499T1 (hr) | Spojevi i postupci za modulaciju kinaze, te odgovarajuće indikacije | |
JP2019518766A5 (ja) | ||
RU2017114687A (ru) | Ингибитор egfr и его получение и применение | |
RU2019101220A (ru) | Кристаллические формы соединения триазолопиримидина | |
RU2018119173A (ru) | Производное бензофурана, способ его получения и его применение в медицине | |
JP2017507175A5 (ja) | ||
JP2013525363A5 (ja) | ||
RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
JP2013535491A5 (ja) | ||
JP2016501221A5 (ja) | ||
JP2016538344A5 (ja) | ||
JP2017511321A5 (ja) | ||
RU2014101626A (ru) | Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты | |
CA2796744A1 (en) | Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | |
JP2016528273A5 (ja) | ||
RU2016133731A (ru) | Функционализованные соединения бензопирана и их применение | |
JP2019522055A5 (ja) | ||
JP2016539985A5 (ja) | ||
RU2017133243A (ru) | Частицы n-(5-циано-4-((2-метоксиэтил)амино)пиридин-2-ил)-7-формил-6-((4-метил-2-оксопиперазин-1-ил)метил)-3,4-дигидро-1,8-нафтиридин-1(2h)-карбоксамида | |
JP2013523680A5 (ja) | ||
JP2015519396A5 (ja) | ||
JP2019510075A5 (ja) |